1. Yanagawa H, Nakamura Y, Yashiro M, Kawasaki T, editors. Epidemiology of Kawasaki disease – a 30-year achievement. Shindan to Chiryo Company Tokyo; 2002 [in Japanese]
2. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: basic pathophysiology. Crit Care Med. 2010;38(2 Suppl):S3–9. http://dx.doi.org/10.1097/CCM.0b013e3181c9cbd9 . PMID:20083911.
3. Lijnen HR, Panekoek H, Vermylen J. Thrombosis and thrombolytic therapy. In: Chien KR, editor. Molecular basis of cardiovascular disease. 2nd ed. Philadelphia: WB Saunders; 2004. p. 519–38.
4. Burns JC, Glode MP, Clarke SH, Wiggins Jr J, Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr. 1984;105(2):206–11. http://dx.doi.org/10.1016/S0022-3476(84)80114-6 . PMID:6235335.
5. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91(1):327–87. http://dx.doi.org/10.1152/physrev.00047.2009 . PMID:21248169.